


PHARMACEUTICAL 2022

ChemoCentryx Inc. Rank 216 of 475



RealRate

PHARMACEUTICAL 2022



ChemoCentryx Inc. Rank 216 of 475

The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 55% points. The greatest weakness of ChemoCentryx Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is -78%, being 198% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	269,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	63,017
Liabilities, Non-Current	51,743
Other Assets	124,206
Other Compr. Net Income	-597
Other Expenses	302
Other Liabilities	24,772
Other Net Income	-1,836
Property and Equipment	32,269
Research and Development	82,990
Revenues	32,224
Selling, General and Administrative Expense	78,851

Output Variable	Value in 1000 USD
Assets	425,652
Liabilities	139,532
Expenses	162,143
Stockholders Equity	286,120
Net Income	-131,755
Comprehensive Net Income	-132,054
Economic Capital Ratio	-78%